Cancer Home > Ofatumumab Dosing

A healthcare provider may recommend ofatumumab (Arzerra®) to people with chronic lymphocytic leukemia (CLL). Specifically, this drug is reserved for those who have not responded to certain other chemotherapy treatment. The dosing guidelines for ofatumumab will be the same for everyone, regardless of age or weight.
This medicine comes as an intravenous (IV) infusion that is administered by a healthcare provider in a healthcare setting. The infusion is given once a week for eight weeks, followed by a dose every four weeks for four doses. Treatment is finished after 12 doses, which normally takes 24 weeks.
(For more information, click Ofatumumab Dosage. This full-length article covers specific dosing guidelines for the drug, as well as details on how this infusion is given and problems to watch out for.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.